Three-year outcomes of preoperative chemoradiotherapy plus nivolumab in microsatellite stable and microsatellite instability-high locally advanced rectal cancer-Reference-Cited by-同舟云学术

Three-year outcomes of preoperative chemoradiotherapy plus nivolumab in microsatellite stable and microsatellite instability-high locally advanced rectal cancer

Published:2024-06-04 Issue:2 Volume:131 Page:283-289
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Tsukada Yuichiro^ORCID,Bando Hideaki,Inamori Koji,Wakabayashi Masashi,Togashi Yosuke^ORCID,Koyama Shohei,Kotani Daisuke^ORCID,Yuki Satoshi,Komatsu Yoshito^ORCID,Homma Shigenori,Taketomi Akinobu^ORCID,Uemura Mamoru,Kato Takeshi,Fukui Makoto,Nakamura Naoki,Kojima Motohiro,Kawachi Hiroshi,Kirsch Richard,Yoshida Tsutomu,Sato Akihiro,Nishikawa Hiroyoshi^ORCID,Ito Masaaki,Yoshino Takayuki^ORCID

Funder

Ono Pharmaceutical Co., Ltd.

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41416-024-02730-7.pdf

Reference30 articles.

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–49.

2. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–40.

3. Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM, Putter H, Kranenbarg EMK, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): A randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:29–42.

4. Conroy T, Bosset JF, Etienne PL, Rio E, François E, Mesgouez-Nebout N, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:702–15.

5. Fokas E, Schlenska-Lange A, Polat B, Klautke G, Grabenbauer GG, Fietkau R, et al. Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for patients with locally advanced rectal cancer: Long-term results of the CAO/ARO/AIO-12 randomized clinical trial. JAMA Oncol. 2022;8:e215445. https://doi.org/10.1001/jamaoncol.2021.5445.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimizing Rectal Cancer Treatment: A Path Towards Personalization;Annals of Oncology;2024-10